

Orexin Receptor Type 2 - Pipeline Review, H1 2020

<https://marketpublishers.com/r/O5C80ED45538EN.html>

Date: April 2020

Pages: 83

Price: US\$ 3,500.00 (Single User License)

ID: O5C80ED45538EN

Abstracts

Orexin Receptor Type 2 - Pipeline Review, H1 2020

SUMMARY

Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) pipeline Target constitutes close to 9 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes. The latest report Orexin Receptor Type 2 - Pipeline Review, H1 2020, outlays comprehensive information on the Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Orexin receptor type 2 (Ox2R or OX2) also known as hypocretin receptor type 2, is a protein that is encoded by the HCRTR2 gene. OX2 is a G-protein coupled receptor expressed exclusively in the brain. OX2 binds both orexin A and orexin B neuropeptides. OX2 is involved in the central feedback mechanism that regulates feeding behavior. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 2, 2, 1 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Respiratory and Toxicology which include indications Narcolepsy, Insomnia, Obstructive Sleep Apnea, Dementia Associated With Alzheimer's Disease, Hypersomnia, Major Depressive Disorder, Opioid Induced Side Effects, Parkinson's Disease and Sleep Disorders.

Furthermore, this report also reviews key players involved in Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information

sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2)

The report reviews Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics and enlists all their major and minor projects

The report assesses Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Overview

Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Therapeutics
Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Therapeutics
Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Companies
Involved in Therapeutics Development

Eisai Co Ltd

Idorsia Pharmaceutical Ltd

Inexia Ltd

Johnson & Johnson

Orexia Ltd

Takeda Pharmaceutical Co Ltd

Yangtze River Pharmaceutical Group

Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Drug Profiles

leborexant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nemorexant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OPN-021 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

seltorexant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize Orexin-2 for Narcolepsy and Sleep Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

suvorexant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAK-925 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAK-994 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

YNT-185 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

YZJ-1139 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Dormant Products

Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Discontinued Products

Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Product Development Milestones

Featured News & Press Releases

Apr 21, 2020: Idorsia's insomnia drug daridorexant passes Phase III study

Jan 23, 2020: Eisai: Dayvigo (Lemborexant) approved for treatment of insomnia in Japan

Dec 27, 2019: Pivotal phase 3 study of DAYVIGO (lemborexant) for the treatment of insomnia disorder published in JAMA network open

Dec 23, 2019: U.S. FDA Approves Eisai's Dayvigo (Lemborexant) for treatment of insomnia in adult patients

Dec 10, 2019: Eisai presents new findings on Lemborexant as potential Sleep-Wake disorder therapy at 12th Clinical Trials on Alzheimer's Disease (CTAD) conference

Dec 02, 2019: Eisai to present latest data on lemborexant at 12th Clinical Trials on Alzheimer's Disease Conference

Nov 22, 2019: A sleeping pill that doesn't make you sway: a new targeted insomnia treatment

Oct 24, 2019: Trial to test insomnia drug for alcohol use disorder

Oct 01, 2019: Minerva Neurosciences announces update on Seltorexant

Sep 27, 2019: Three new analyses of data expand understanding of the potential role for investigational agent Lemborexant in Insomnia and Irregular Sleep-Wake Rhythm Disorder

Sep 26, 2019: New data presented on TAK-994, an oral selective OX2R agonist at World Sleep Congress

Sep 26, 2019: New data presented at World Sleep Congress demonstrate early signs of efficacy for TAK-925,, a selective orexin type-2 receptor (OX2R) agonist, in patients with narcolepsy type 1

Sep 19, 2019: Eisai to present latest data on Lemborexant at World Sleep Congress

Jul 11, 2019: Latest data on Eisai's lemborexant to be presented at Alzheimer's Association International Conference (AAIC) 2019

Jun 24, 2019: Minerva Neurosciences announces achievement of primary and key secondary objectives in phase 2b clinical trial of Seltorexant (MIN-202) in Insomnia Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indication, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by Eisai Co Ltd, H1 2020
Pipeline by Idorsia Pharmaceutical Ltd, H1 2020
Pipeline by Inexia Ltd, H1 2020
Pipeline by Johnson & Johnson, H1 2020
Pipeline by Orexia Ltd, H1 2020
Pipeline by Takeda Pharmaceutical Co Ltd, H1 2020
Pipeline by Yangtze River Pharmaceutical Group, H1 2020
Dormant Projects, H1 2020
Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Therapy Areas, H1 2020

Number of Products under Development by Top 10 Indications, H1 2020

Number of Products by Mechanism of Actions, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Molecule Types, H1 2020

Number of Products by Stage and Molecule Types, H1 2020

COMPANIES MENTIONED

Eisai Co Ltd

Idorsia Pharmaceutical Ltd

Inexia Ltd

Johnson & Johnson

Orexia Ltd

Takeda Pharmaceutical Co Ltd

Yangtze River Pharmaceutical Group

I would like to order

Product name: Orexin Receptor Type 2 - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/O5C80ED45538EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/O5C80ED45538EN.html>